InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
Stock Information for InflaRx N.V.
Loading
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.